Clinical Trials
231 trialsMedical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer
University of Southern California
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Impact of Fusobacterium Nucleatum on Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Barretos Cancer Hospital
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Memorial Sloan Kettering Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures
Intuitive Surgical
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
FRONE
Institut Bergonié
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
National Cancer Institute (NCI)
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
National Cancer Institute (NCI)
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
Screening With a DNA Blood Test to Address Colorectal Cancer Inequities
University of California, San Diego
STARTRK-2
Hoffmann-La Roche
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
National Cancer Institute (NCI)
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
TRIBE-C
Sun Yat-sen University
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
University of Illinois at Chicago
MK-3475-C66
Merck Sharp & Dohme LLC
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NEST-1
Weill Medical College of Cornell University
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
PARERE
Gruppo Oncologico del Nord-Ovest
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion
University of Southern California
AMPLIFY-7P
Elicio Therapeutics
CLOVER
CytoDyn, Inc.
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
Massachusetts General Hospital
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
ECLIPSE
Guardant Health, Inc.
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
BioNTech SE
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
AbbVie
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
RESOLUTE
Australasian Gastro-Intestinal Trials Group
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
COPERNIC
Jules Bordet Institute
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Institutes of Health Clinical Center (CC)